Viral hepatitis C (VHC) infection is associated with many systemic diseases. Amongst these, the association with ischemic heart disease is underdiagnosed in Sub-Saharan Africa context. We present a case of acute coronary syndrome in a Cameroonian patient with viral hepatitis C with low cardiovascular risk. A 75 years old female followed up for hepatocellular carcinoma secondary to VHC cirrhosis. She was admitted in the hospital for a sudden, resting, intense constrictive thoracic pain lasting more than one hour. This patient initially consulted the gastroenterologist, but secondarily the cardiologist 24 hours after the previous consultation. The initial workup showed ST segment elevation in lead V1 to V4 with Q Wave in the same territory and elevated value of Troponin Ius and CPKMB. Cardiac ultrasonography found akinesia in the anteroseptal and apical segments. Other biological exams showed a dyslipidemia without other cardiovascular risk factors. Despite poor financial resources, the patient was managed with Enoxaparine 8000 UI/12H, Clopidogrel 75mg/24H, Aspirine 100mg/24h. Rosuvastatine 10Mg/24h, Ramipril 2,5mg/24h and Nebivolol 2.5mg/24h, tramadol 100mg/8h, trimetazidine 35mg/12h, omeprazole 40mg/24h, molsidomine 1mg/8h. The pain disappeared 24hours after the beginning of the treatment. In sub-Saharan Africa with high burden of viral hepatitis C infection, we should consider this possibility in patients who present ischemic heart disease with lowcardiovascular risk.
| Published in | Cardiology and Cardiovascular Research (Volume 3, Issue 1) |
| DOI | 10.11648/j.ccr.20190301.15 |
| Page(s) | 18-21 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2019. Published by Science Publishing Group |
Acute Coronary Syndrome, Viral Hepatitis C, Sub-Saharan Africa
| [1] | Fabian Sanchis-Gomar, Carme Perez and al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016 jul; 4 (13): 256. |
| [2] | Lukwiga Onen CHURCHILL. Epidemiology of ischaemic heart disease in sub-saharan Africa. Cardiovascular J Africa. 2013; 24 (2): 34-42. |
| [3] | Rachel Hajar et al. Risk factors for coronaryarterydisease: historicalperspectives. Heart views. 2017; 18 (3): 109-114. |
| [4] | Libby P, Theroux p. pathophysiology of coronaryartery disease. AHA. 2005; 111: 3481-3488. |
| [5] | Obama Shoeib, Medhat Ashmawy et al. Association between coronary artery disease and hepatitis C virus seropositivity. EMHJ- vol. 24 N. 7-2018. |
| [6] | A. Gilbert and G. Lion, “Arterites infectieuses experimentales,” C R Hebd Seances Soc Biol Fil, vol. 41, pp. 583–584, 1889. |
| [7] | J. Bigna, Marie Amougou et al. seroprevalence of hepatitis C virus infection in Cameroon: a systematic review and meta-analysis. BMJ. Vol. 7, no 8.2017. |
| [8] | Salvatore Petta. Hepatitis C and cardiovascular: A review. Journal of Advanced Research (2017) 8, 161–16. |
| [9] | R. Zampino, A. Marrone, L. Restivo et al., “Chronic HCV infection and inflammation: clinical impact on hepatic and extrahepatic manifestations,” World Journal of Hepatology, vol. 5, no. 10, pp. 528–540, 2013. |
| [10] | N. Ishizaka, Y. Ishizaka, E. Takahashi et al., “Association between hepatitis C virus seropositivity, carotid-artery plaque and intima-media thickening,” The Lancet, vol. 359, no. 9301, pp. 133–135, 2002. |
| [11] | Marwan S. Abougergi, Raffi Karagozian et al. ST Elevation Myocardial Infarction Mortality Among Patients With Liver Cirrhosis: A Nationwide Analysis Across a Decade. J Clin Gastroenterol, Vol. 49, no. 9, pp. 778-782, 2015. |
| [12] | Petta S., Torres D. et al. Carotid athererosclerosis and chronic hepatitis C: a prospective study of risk associations; hepatology. 2012; 55: 1317-1323. (PubMed). |
| [13] | Vassale C, Masini S et al. Evidence for association between hepatitis virus seropositivity and coronary artery disease. Heart 2004; 90: 565-566. |
| [14] | Alyan O, Kacmaz F et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified reardonseveritry score system. Circ J. 2008; 72: 1960-1965. |
| [15] | Völzke H, Schwahn C et al. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 2004; 174: 99-103. |
| [16] | Boddi M, Abbate R et al. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCN RNA localization in human carotid plaques. Dig Liver Dis 2007; 39: S55-S60. |
| [17] | Salam RA, Baher N et al. Prevalence of hepatitis C Virus Seropositivity and its impact on coronary artery disease among Egyptian patients referred for coronary angiography. Cardiol Res Pract. 2016. |
APA Style
Helles Murielle Lema, Mazou Ngou Temgoua, Ngam Mary Engonwei, Mounpou Blaise, Tonleu Carole, et al. (2019). Acute Coronary Syndrome in Patient with Viral Hepatitis C: An Underdiagnosed Condition in Sub-Saharan Africa. Cardiology and Cardiovascular Research, 3(1), 18-21. https://doi.org/10.11648/j.ccr.20190301.15
ACS Style
Helles Murielle Lema; Mazou Ngou Temgoua; Ngam Mary Engonwei; Mounpou Blaise; Tonleu Carole, et al. Acute Coronary Syndrome in Patient with Viral Hepatitis C: An Underdiagnosed Condition in Sub-Saharan Africa. Cardiol. Cardiovasc. Res. 2019, 3(1), 18-21. doi: 10.11648/j.ccr.20190301.15
AMA Style
Helles Murielle Lema, Mazou Ngou Temgoua, Ngam Mary Engonwei, Mounpou Blaise, Tonleu Carole, et al. Acute Coronary Syndrome in Patient with Viral Hepatitis C: An Underdiagnosed Condition in Sub-Saharan Africa. Cardiol Cardiovasc Res. 2019;3(1):18-21. doi: 10.11648/j.ccr.20190301.15
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ccr.20190301.15,
author = {Helles Murielle Lema and Mazou Ngou Temgoua and Ngam Mary Engonwei and Mounpou Blaise and Tonleu Carole and Mefire Aicha and Ahinaga Andre Jules and Boombhi Jerome and Menanga Alain},
title = {Acute Coronary Syndrome in Patient with Viral Hepatitis C: An Underdiagnosed Condition in Sub-Saharan Africa},
journal = {Cardiology and Cardiovascular Research},
volume = {3},
number = {1},
pages = {18-21},
doi = {10.11648/j.ccr.20190301.15},
url = {https://doi.org/10.11648/j.ccr.20190301.15},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ccr.20190301.15},
abstract = {Viral hepatitis C (VHC) infection is associated with many systemic diseases. Amongst these, the association with ischemic heart disease is underdiagnosed in Sub-Saharan Africa context. We present a case of acute coronary syndrome in a Cameroonian patient with viral hepatitis C with low cardiovascular risk. A 75 years old female followed up for hepatocellular carcinoma secondary to VHC cirrhosis. She was admitted in the hospital for a sudden, resting, intense constrictive thoracic pain lasting more than one hour. This patient initially consulted the gastroenterologist, but secondarily the cardiologist 24 hours after the previous consultation. The initial workup showed ST segment elevation in lead V1 to V4 with Q Wave in the same territory and elevated value of Troponin Ius and CPKMB. Cardiac ultrasonography found akinesia in the anteroseptal and apical segments. Other biological exams showed a dyslipidemia without other cardiovascular risk factors. Despite poor financial resources, the patient was managed with Enoxaparine 8000 UI/12H, Clopidogrel 75mg/24H, Aspirine 100mg/24h. Rosuvastatine 10Mg/24h, Ramipril 2,5mg/24h and Nebivolol 2.5mg/24h, tramadol 100mg/8h, trimetazidine 35mg/12h, omeprazole 40mg/24h, molsidomine 1mg/8h. The pain disappeared 24hours after the beginning of the treatment. In sub-Saharan Africa with high burden of viral hepatitis C infection, we should consider this possibility in patients who present ischemic heart disease with lowcardiovascular risk.},
year = {2019}
}
TY - JOUR T1 - Acute Coronary Syndrome in Patient with Viral Hepatitis C: An Underdiagnosed Condition in Sub-Saharan Africa AU - Helles Murielle Lema AU - Mazou Ngou Temgoua AU - Ngam Mary Engonwei AU - Mounpou Blaise AU - Tonleu Carole AU - Mefire Aicha AU - Ahinaga Andre Jules AU - Boombhi Jerome AU - Menanga Alain Y1 - 2019/03/26 PY - 2019 N1 - https://doi.org/10.11648/j.ccr.20190301.15 DO - 10.11648/j.ccr.20190301.15 T2 - Cardiology and Cardiovascular Research JF - Cardiology and Cardiovascular Research JO - Cardiology and Cardiovascular Research SP - 18 EP - 21 PB - Science Publishing Group SN - 2578-8914 UR - https://doi.org/10.11648/j.ccr.20190301.15 AB - Viral hepatitis C (VHC) infection is associated with many systemic diseases. Amongst these, the association with ischemic heart disease is underdiagnosed in Sub-Saharan Africa context. We present a case of acute coronary syndrome in a Cameroonian patient with viral hepatitis C with low cardiovascular risk. A 75 years old female followed up for hepatocellular carcinoma secondary to VHC cirrhosis. She was admitted in the hospital for a sudden, resting, intense constrictive thoracic pain lasting more than one hour. This patient initially consulted the gastroenterologist, but secondarily the cardiologist 24 hours after the previous consultation. The initial workup showed ST segment elevation in lead V1 to V4 with Q Wave in the same territory and elevated value of Troponin Ius and CPKMB. Cardiac ultrasonography found akinesia in the anteroseptal and apical segments. Other biological exams showed a dyslipidemia without other cardiovascular risk factors. Despite poor financial resources, the patient was managed with Enoxaparine 8000 UI/12H, Clopidogrel 75mg/24H, Aspirine 100mg/24h. Rosuvastatine 10Mg/24h, Ramipril 2,5mg/24h and Nebivolol 2.5mg/24h, tramadol 100mg/8h, trimetazidine 35mg/12h, omeprazole 40mg/24h, molsidomine 1mg/8h. The pain disappeared 24hours after the beginning of the treatment. In sub-Saharan Africa with high burden of viral hepatitis C infection, we should consider this possibility in patients who present ischemic heart disease with lowcardiovascular risk. VL - 3 IS - 1 ER -
Information
Email: